

Helmut Jonuleit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5111413/publications.pdf>

Version: 2024-02-01

106
papers

13,584
citations

66343

42
h-index

36028

97
g-index

114
all docs

114
docs citations

114
times ranked

12795
citing authors

#	ARTICLE	IF	CITATIONS
1	ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Cancer Gene Therapy, 2021, 28, 359-374.	4.6	9
2	In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model. International Journal of Molecular Sciences, 2021, 22, 1011.	4.1	6
3	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. International Immunology, 2021, 33, 435-446.	4.0	14
4	Abstract 1847: Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+regulatory T cells. , 2021, , .		0
5	ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death and Disease, 2021, 12, 969.	6.3	13
6	RAF kinases are stabilized and required for dendritic cell differentiation and function. Cell Death and Differentiation, 2020, 27, 1300-1315.	11.2	15
7	Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1314-1325.	6.4	19
8	Humanized mice in cutaneous leishmaniasisâ€”Suitability analysis of human PBMC transfer into immunodeficient mice. Experimental Dermatology, 2019, 28, 1087-1090.	2.9	4
9	Dendritic Mesoporous Silica Nanoparticles for pHâ€Stimuliâ€Responsive Drug Delivery of TNFâ€Alpha. Advanced Healthcare Materials, 2017, 6, 1700012.	7.6	46
10	Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumorâ€Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice. ChemMedChem, 2017, 12, 1424-1428.	3.2	24
11	Drug Delivery: Dendritic Mesoporous Silica Nanoparticles for pHâ€Stimuliâ€Responsive Drug Delivery of TNFâ€Alpha (Adv. Healthcare Mater. 13(2017)). Advanced Healthcare Materials, 2017, 6, .	7.6	2
12	TCR signalling network organization at the immunological synapses of murine regulatory T cells. European Journal of Immunology, 2017, 47, 2043-2058.	2.9	9
13	Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells. International Journal of Molecular Sciences, 2017, 18, 271.	4.1	29
14	Bioconjugation of Small Molecules to RNA Impedes Its Recognition by Toll-Like Receptor 7. Frontiers in Immunology, 2017, 8, 312.	4.8	8
15	Novel Concept of CD4-Mediated Activation of Regulatory T Cells for the Treatment of Graft-Versus-Host Disease. Frontiers in Immunology, 2017, 8, 1495.	4.8	4
16	Editorial: Current Concepts of Cellular and Biological Drugs to Modulate Regulatory T Cell Activity in the Clinic. Frontiers in Immunology, 2016, 7, 141.	4.8	0
17	<scp>GARP</scp> inhibits allergic airway inflammation in a humanized mouse model. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1274-1283.	5.7	17
18	Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. Nanomedicine, 2016, 11, 2699-2709.	3.3	19

#	ARTICLE	IF	CITATIONS
19	Kinome Profiling of Regulatory T Cells: A Closer Look into a Complex Intracellular Network. PLoS ONE, 2016, 11, e0149193.	2.5	6
20	A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget, 2016, 7, 42996-43009.	1.8	26
21	Pillars Article: Induction of Tolerance by IL-10-Treated Dendritic Cells. J. Immunol. 1997. 159: 4772-4780. Journal of Immunology, 2016, 197, 1547-55.	0.8	6
22	Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. International Journal of Molecular Sciences, 2015, 16, 16330-16346.	4.1	25
23	Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nature Immunology, 2015, 16, 267-275.	14.5	102
24	A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunology and Cell Biology, 2015, 93, 396-405.	2.3	34
25	FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1811-1822.	3.0	37
26	IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity. International Journal of Cancer, 2015, 136, 821-830.	5.1	22
27	GARP reduces inflammation in a humanized mouse model of allergic airway disease. , 2015, , .		0
28	Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. International Immunopharmacology, 2014, 18, 347-357.	3.8	28
29	Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice. Journal of NeuroImmune Pharmacology, 2013, 8, 1037-1047.	4.1	17
30	Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain, 2013, 136, 1048-1066.	7.6	100
31	Costimulatory Molecules on Immunogenic Versus Tolerogenic Human Dendritic Cells. Frontiers in Immunology, 2013, 4, 82.	4.8	180
32	Synthesis of Maleimide-Functionalized HPMA-Copolymers and in vitro Characterization of the aRAGE- and Human Immunoglobulin (hulG)-Polymer Conjugates. Macromolecular Bioscience, 2013, 13, 203-214.	4.1	14
33	Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. Blood, 2013, 122, 1182-1191.	1.4	58
34	Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis. PLoS ONE, 2013, 8, e77634.	2.5	40
35	Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3 ⁺ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16258-16263.	7.1	123
36	Boosting regulatory T cell function by CD4 stimulation enters the clinic. Frontiers in Immunology, 2012, 3, 164.	4.8	15

#	ARTICLE	IF	CITATIONS
37	Plasmacytoid Dendritic Cells Are Inefficient in Activation of Human Regulatory T Cells. PLoS ONE, 2012, 7, e44056.	2.5	7
38	CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. Journal of Allergy and Clinical Immunology, 2012, 129, 521-528.e7.	2.9	28
39	Allergen-induced IgE-dependent gut inflammation in a human PBMCâ€“engrafted murine model of allergy. Journal of Allergy and Clinical Immunology, 2012, 129, 1126-1135.	2.9	35
40	Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. European Journal of Immunology, 2012, 42, 569-572.	2.9	29
41	Research in practice: Regulatory T cells â€“ targets for therapeutic approaches?. JDDG - Journal of the German Society of Dermatology, 2011, 9, 8-11.	0.8	1
42	Forschen fÃ¼r die Praxis: Regulatorische T-Zellen - Therapeutische Zielzellen?. JDDG - Journal of the German Society of Dermatology, 2011, 9, 8-11.	0.8	0
43	Interferon-Î± Abrogates Tolerance Induction by Human Tolerogenic Dendritic Cells. PLoS ONE, 2011, 6, e22763.	2.5	11
44	Lysozyme Mâ€“Positive Monocytes Mediate Angiotensin IIâ€“Induced Arterial Hypertension and Vascular Dysfunction. Circulation, 2011, 124, 1370-1381.	1.6	422
45	Immune regulation by dendritic cells and T cellsâ€“basic science, diagnostic, and clinical application. Clinical Laboratory, 2011, 57, 1-12.	0.5	13
46	Increased regulatory Tâ€“cell frequencies in patients with advanced melanoma correlate with a generally impaired Tâ€“cell responsiveness and are restored after dendritic cellâ€“based vaccination. Experimental Dermatology, 2010, 19, e213-21.	2.9	41
47	Generation of monoclonal antibodies against human regulatory T cells. Journal of Immunological Methods, 2010, 353, 62-70.	1.4	5
48	Large scale preparation of human MHC class II+ integrin Î²1+ Tregs. Journal of Immunological Methods, 2010, 360, 96-102.	1.4	1
49	CD40 signalling induces ILâ€“10â€“producing, tolerogenic dendritic cells. Experimental Dermatology, 2010, 19, 44-53.	2.9	36
50	Human primary dendritic cell subsets differ in their ILâ€“12 release in response to <i>Leishmania major</i> infection. Experimental Dermatology, 2010, 19, 924-926.	2.9	12
51	The Role of ICOS in Directing T Cell Responses: ICOS-Dependent Induction of T Cell Anergy by Tolerogenic Dendritic Cells. Journal of Immunology, 2009, 182, 3349-3356.	0.8	81
52	Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?. Human Immunology, 2009, 70, 289-293.	2.4	74
53	Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood, 2009, 114, 1263-1269.	1.4	67
54	miR-155 Inhibition Sensitizes CD4+ Th Cells for TREG Mediated Suppression. PLoS ONE, 2009, 4, e7158.	2.5	79

#	ARTICLE	IF	CITATIONS
55	Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. Journal of Experimental Medicine, 2007, 204, 1303-1310.	8.5	524
56	Regulatory T cells—the renaissance of the suppressor T cells. Annals of Medicine, 2007, 39, 322-334.	3.8	22
57	Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood, 2007, 110, 1550-1558.	1.4	181
58	CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. European Journal of Immunology, 2007, 37, 1217-1223.	2.9	29
59	Dendritic Cell-Based Immunotherapy of Malignant Melanoma: Success and Limitations. JDDG - Journal of the German Society of Dermatology, 2007, 5, 190-196.	0.8	32
60	Immuntherapie des Malignen Melanoms mit Dendritischen Zellen: Erfolge und Grenzen. JDDG - Journal of the German Society of Dermatology, 2007, 5, ---.	0.8	0
61	Oxymetazoline modulates proinflammatory cytokines and the T-cell stimulatory capacity of dendritic cells. Experimental Dermatology, 2007, 16, 171-178.	2.9	15
62	Regulatory T cells: present facts and future hopes. Medical Microbiology and Immunology, 2006, 195, 113-124.	4.8	23
63	Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. International Journal of Cancer, 2006, 118, 2617-2627.	5.1	57
64	Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Annals of Oncology, 2006, 17, 563-570.	1.2	400
65	Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Cp96 Amplifies Innate and Adaptive Immune Responses. Journal of Biological Chemistry, 2006, 281, 22545-22553.	3.4	119
66	Regulatory T-Cells in Antitumor Therapy: Isolation and Functional Testing of CD4 ⁺ CD25 ⁺ Regulatory T-Cells. , 2005, 109, 285-296.		12
67	Dendritic Cells: Sentinels of Immunity and Tolerance. International Journal of Hematology, 2005, 81, 197-203.	1.6	49
68	Differential Regulatory Capacity of CD25+ T Regulatory Cells and Preactivated CD25+ T Regulatory Cells on Development, Functional Activation, and Proliferation of Th2 Cells. Journal of Immunology, 2004, 173, 267-274.	0.8	98
69	Early Adenoviral Gene Expression Mediates Immunosuppression by Transduced Dendritic Cell (DC): Implications for Immunotherapy Using Genetically Modified DC. Journal of Immunology, 2004, 172, 1524-1530.	0.8	17
70	Human CD25 ⁺ regulatory T cells: two subsets defined by the integrins $\alpha_4\beta_7$ or $\alpha_4\beta_1$ confer distinct suppressive properties upon CD4 ⁺ T helper cells. European Journal of Immunology, 2004, 34, 1303-1311.	2.9	165
71	Human CD4+CD25+ regulatory T cells and infectious tolerance.. Transplantation, 2004, 77, S23-S25.	1.0	62
72	Priming of T cells with aAd-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Therapy, 2003, 10, 243-250.	4.5	40

#	ARTICLE	IF	CITATIONS
73	The Regulatory T Cell Family: Distinct Subsets and their Interrelations. Journal of Immunology, 2003, 171, 6323-6327.	0.8	383
74	Immune regulation by regulatory T cells: implications for transplantation. Transplant Immunology, 2003, 11, 267-276.	1.2	48
75	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. Journal of Immunology, 2003, 170, 1257-1266.	0.8	842
76	Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and Dendritic Cells: Superiority of HSP60. Journal of Immunology, 2002, 169, 6141-6148.	0.8	157
77	Infectious Tolerance. Journal of Experimental Medicine, 2002, 196, 255-260.	8.5	582
78	ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. European Journal of Immunology, 2002, 32, 2680-2686.	2.9	114
79	Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunology and Cell Biology, 2002, 80, 477-483.	2.3	324
80	Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in Immunology, 2001, 22, 394-400.	6.8	432
81	How do dendritic cells prevent autoimmunity: what is a mature dendritic cell in the mouse?. Trends in Immunology, 2001, 22, 547.	6.8	0
82	A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 2001, 93, 243-251.	5.1	353
83	Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood. Journal of Experimental Medicine, 2001, 193, 1285-1294.	8.5	1,114
84	Expression of the Actin-Bundling Protein Fascin in Cultured Human Dendritic Cells Correlates with Dendritic Morphology and Cell Differentiation. Journal of Investigative Dermatology, 2000, 115, 658-663.	0.7	73
85	Fetal Calf Serum-Free Generation of Functionally Active Murine Dendritic Cells Suitable for In Vivo Therapeutic Approaches. Journal of Investigative Dermatology, 2000, 114, 142-148.	0.7	24
86	Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Therapy, 2000, 7, 249-254.	4.5	61
87	Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Archives of Dermatological Research, 2000, 292, 325-332.	1.9	28
88	Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Archives of Dermatological Research, 2000, 292, 437-445.	1.9	64
89	Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells. Journal of Immunology, 2000, 165, 3492-3496.	0.8	200
90	Induction of Interleukin 10-Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells. Journal of Experimental Medicine, 2000, 192, 1213-1222.	8.5	1,425

#	ARTICLE	IF	CITATIONS
91	Interleukin-10â€“Treated Human Dendritic Cells Induce a Melanoma-Antigenâ€“Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells. Blood, 1999, 93, 1634-1642.	1.4	456
92	Vaccination with Mage-3a1 Peptideâ€“Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma. Journal of Experimental Medicine, 1999, 190, 1669-1678.	8.5	1,140
93	Allergen-specific immune deviation from a T H2 to a T H1 response induced by dendritic cells and collagen type I. Journal of Allergy and Clinical Immunology, 1999, 104, 1052-1059.	2.9	16
94	Interleukin-10â€“Treated Human Dendritic Cells Induce a Melanoma-Antigenâ€“Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells. Blood, 1999, 93, 1634-1642.	1.4	29
95	Influence of extracellular matrix proteins on the development of cultured human dendritic cells. European Journal of Immunology, 1998, 28, 1673-1680.	2.9	65
96	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology, 1998, 28, 3231-3239.	2.9	274
97	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. , 1998, 28, 3231.		1
98	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology, 1998, 28, 3231-3239.	2.9	3
99	Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology, 1997, 27, 3135-3142.	2.9	1,087
100	Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. International Journal of Cancer, 1997, 73, 309-316.	5.1	322
101	Dendritic cells as mediators of tumorâ€“induced tolerance in metastatic melanoma. International Journal of Cancer, 1997, 73, 309-316.	5.1	0
102	Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Archives of Dermatological Research, 1996, 289, 1-8.	1.9	90
103	Specific stabilization of the 4F7 molecule on dendritic cells by contact allergens. Archives of Dermatological Research, 1996, 288, 745-752.	1.9	3
104	Specific stabilization of the 4F7 molecule on dendritic cells by contact allergens. Archives of Dermatological Research, 1996, 288, 745-752.	1.9	0
105	Functional and morphological characterization of 4F7+ spleen accessory dendritic cells. International Immunology, 1993, 5, 615-624.	4.0	10
106	Differential analysis of T cell membrane proteins. , 0, 2004, .		0